ACB vs SNDL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACB and SNDL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACB and SNDL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself. Once one of the most hyped names of the 2018-2019 cannabis boom, it has since exited low-margin Canadian consumer (recreational) cannabis and non-core operations to concentrate on global medical cannabis, which carries higher and more durable margins. In its fiscal 2026 (ended March 31, 2026) the company reported record medical results: global medical net revenue grew sharply, international medical revenue rose even faster (led by Germany and Poland), and adjusted EBITDA and free cash flow were positive, a real shift from years of cash burn. On a GAAP basis, however, Yahoo Finance data show fiscal 2026 revenue of about 321 million and a net loss of about 122 million (Canadian dollars), with large losses in two quarters. International medical, its highest-margin segment, now makes up a majority of medical revenue. To feed that demand, Aurora acquired Safari Flower Company, an EU-GMP certified European cultivator, completed the divestiture of its controlling stake in Bevo Agtech in February 2026, and in October 2026 finished an expansion of its European EU-GMP facility that it says more than doubles expected annual flower output.

Full ACB guide

SNDL Inc. (Nasdaq: SNDL), headquartered in Calgary, Alberta, is one of the largest private-sector retailers of liquor and cannabis in Canada and also operates a cannabis production business and a portfolio of cannabis-related investments. The company reports through four segments: Liquor Retail (banners including Wine and Beyond, Liquor Depot, and Ace Liquor), Cannabis Retail (banners including Value Buds, Spiritleaf, and Cost Cannabis, spanning roughly 190 locations as of early 2026), Cannabis Operations (cultivation, manufacturing, and branded products sold across Canada and internationally), and Investments. This structure makes SNDL unusual in the cannabis space because a large share of its revenue comes from the relatively stable business of selling regulated alcohol, which cushions the more volatile cannabis segments.

Full SNDL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACB drivers: International medical cannabis growth; The Curaleaf bid and strategic review.
• SNDL drivers: Retail Scale Across Liquor and Cannabis; Debt-Free Balance Sheet and Cash Position.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. For SNDL, the dominant risk is profitability: despite roughly C$946 million of annual revenue, SNDL has struggled to produce consistent net income, reporting a net loss of about C$6 million for full-year 2025 and only break-even adjusted operating income, so margins remain thin and can turn negative.

Pick ACB if you believe its drivers more; SNDL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACB and SNDL guides.

ACB. Aurora trades below book value and under one times sales, a discount that tracks its losses and dilution history, but in October 2026 the price is also being set by the Curaleaf bid: the shares sit about 20% below the roughly $5 headline offer, since most of that value is in Curaleaf stock and the board opposes it. Be cautious with per-share comparisons across time given the reverse-split history, and check the current share count, cash position, and the status of the offer directly in filings. Fiscal second-quarter results are expected in early November 2026.

SNDL. SNDL's valuation is unusual because much of its worth sits in cash and investments rather than in current earnings. With trailing net losses, traditional P/E multiples are not meaningful, so investors often look at its ~0.34 times sales, its cash balance and the carrying value of its Investments segment relative to a market capitalization of ~US$313 million. Management's own proposed issuer bid at up to US$1.35 a share, above the October 16 close of US$1.27, is the clearest signal of how the company views that gap; third-quarter results on October 27, 2026 will show whether revenue has stopped shrinking.

Headline figures (approximate, October 2026): ACB shows market cap ~$252M at ~$3.98 a share (Oct 16, 2026), revenue (ttm) ~314M (Canadian dollars), down ~9% YoY in the latest quarter, net income (ttm) ~-52M; Q1 FY2027 net loss only ~-4M, eps (latest quarter) ~-$0.07 vs ~-$0.21 estimate; SNDL shows net revenue (ttm) ~C$928 million (FY2025 ~C$946 million), net revenue (q2 2026) ~C$235.8 million (down ~3.7% YoY), gross margin (ttm) ~26.2%, net income / loss Q2 2026 net loss ~C$7.8 million; TTM net loss ~C$21.7 million.

ACB and SNDL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACB and SNDL exposure against your real portfolio. It is not an investment adviser.